Navigation Links
First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer
Date:1/11/2011

SUNNYVALE, Calif., Jan. 11, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today the first published five-year outcomes on low risk prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System. The multi-center study, published in the January 10, 2011 issue of Radiation Oncology, found that 93 percent of patients had no recurrence of their cancer at a median follow-up of five years, a rate that compares favorably to results obtained with other treatment modalities, including surgery and conventional radiation therapy.

The study, "Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: Five-Year Outcomes," combined data from 41 patients treated at Stanford University in Stanford, Calif. and Naples Community Hospital in Naples, Fla. with a median follow-up of five years. The paper represents the longest published study to date on the use of CyberKnife radiosurgery, also referred to as stereotactic body radiotherapy (SBRT), as a treatment approach for clinically localized, low-risk prostate cancer. In addition to demonstrating high five-year disease-free survival rates, the study also found generally low levels of urinary and rectal toxicity following the five-day course of treatment, concluding that  CyberKnife radiosurgery can achieve high rates of disease control while sparing critical structures, thereby minimizing undesirable side effects typically associated with prostate cancer treatments and preserving patients' quality of life.

"As a non-invasive treatment option completed in just five visits, stereotactic radiotherapy with the CyberKnife System offers pati
'/>"/>

SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Consolidated Net Profit increased ... Highlights   , India Business grew by 20.87% ... to Rs. 4,886.70 Mn Rest of World (ROW) Business ... Business grew by 34.53% to Rs. 977.26 Mn Latin ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- Delivery ... once order is placed. Photo - ... a professional and in-depth market survey on Global ... reviews the basic information of Hemodialysis Machine including ... then explores global and China,s top manufacturers of ...
(Date:7/24/2014)... Scotland , July 24, 2014 Cancer patients ... gain access to state-of-the-art cancer treatment closer to home when ... next year. Varian Medical Systems (NYSE: VAR ... an order was placed in June for four TrueBeam™ medical ... systems, which offer fast and efficient radiotherapy and radiosurgery treatments, ...
Breaking Medicine Technology:Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... Incorporated (Nasdaq: ARAY ), the premier radiation oncology ... Euan S. Thomson, Ph.D., is scheduled to present at the ... City on Tuesday November 15, 2011 at 10:30 a.m. EST/7:30 ... the Stephens Fall Investment Conference in New York City on ...
... PARSIPPANY, N.J., Nov. 10, 2011 Columbia Laboratories, Inc. ... (NYSE: WPI ), today confirmed that the ... Food and Drug Administration (FDA) is scheduled to review ... for the reduction of risk of preterm birth in ...
Cached Medicine Technology:Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 2Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 3Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 4
(Date:7/24/2014)... Newark, NJ (PRWEB) July 24, 2014 ... which will give one lucky family a rent-free week ... only until August 3, 2014. Don’t miss your chance ... The sweepstakes is open to all New Jersey residents, ... Horizon BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , ...
(Date:7/24/2014)... with high-throughput data generated by breast cancer biologists ... computational method to determine how gene networks are ... as they respond to potential cancer therapy agents., ... each other in laboratory-grown cells is described in ... PLOS Computational Biology . , The method ...
(Date:7/24/2014)... Human Papillomavirus Vaccination (HPV) even after becoming sexually ... results than those who were never vaccinated. These ... Diseases . , Researchers from Boston University ... conducted a cross-sectional study of 235 women age ... HPV status and demographic and behavioral characteristics were ...
(Date:7/24/2014)... Los Angeles, CA (PRWEB) July 24, 2014 ... (FDA), American Optometric Association (AOA) and the Entertainment ... artists from the TV series American Horror Story ... to bring the dramatic realities of illegal ... public service campaign, which has already reached tens-of-thousands, ...
(Date:7/24/2014)... 4th Annual National Venous Interventional Summit is available ... an established Venous Endovascular Interventional Strategies group comprised ... is to provide a "How To" meeting for ... in advancing their knowledge and skills in venous ... own comprehensive venous interventional program. Topics at this ...
Breaking Medicine News(10 mins):Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2
... announced today that,the physicians of Great Lakes Radiologists, one of ... Aurora Medical Group. , ... and,clinics. , "These are ... care we provide for Aurora patients," said Jeff Bailet, M.D., ...
... and Management Realigned to Provide Full Support for Clinical ... Md., Dec. 15 EntreMed, Inc. (Nasdaq: ... to focus the Company,s resources on its most promising ... part of the Company,s overall plan to lower operating ...
... 15, 2008 Researchers from Yale University School ... magnification to standard white light colonoscopy in differentiating ... NBI was not more accurate than white light ... curve for these experienced endoscopists using NBI as ...
... brakes on killer disease, scientists say , , MONDAY, Dec. ... gene may provide a new target for treating deadly ... Mayo Clinic College of Medicine in Minnesota show the ... in another gene that, in a mutated form, has ...
... Imaging(R),Inc., a wholly owned subsidiary of Mercury Computer ... it has received FDA 510(k) clearance to market,its ... This release brings,significant enhancements to its prior offerings ... Neuroradiology and Oncology applications. The Neuro,option facilitates brain ...
... 15 Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: ... in the Clinical and Sports Nutrition Market, announces financial results ... , Net revenue for the third ... in the third quarter 2007. The Company reduced its, ...
Cached Medicine News:Health News:Great Lakes Radiologists to Join Aurora Medical Group 2Health News:EntreMed Focuses on Development of ENMD-2076 2Health News:EntreMed Focuses on Development of ENMD-2076 3Health News:EntreMed Focuses on Development of ENMD-2076 4Health News:EntreMed Focuses on Development of ENMD-2076 5Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 2Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 3Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 4Health News:Pancreatic Cancer May Have a New Foe 2Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 2Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 3Health News:Visage Imaging Receives FDA 510(k) Clearance for its Latest Thin Client Product Release 4Health News:Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results 2Health News:Millennium Biotechnologies Reports Strong Third Quarter Revenue and Financial Results 3
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... glucose monitor elevates bedside glucose testing to ... approaches the quality of central laboratory testing. ... measuring strip technology. Current glucose strips ... Multi-Well system measures and corrects hematocrit interference ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... The BreatheX is a wearable CPAP ... treatment of sleep apnea. The lightweight BreatheX ... of therapy with its built-in, rechargeable battery, ... users will no longer need to be ...
Medicine Products: